Related by context. All words. (Click for frequent words.) 91 SPEAR Study 69 Combination REOLYSIN R 68 Phase 2b Clinical Trial 68 systemic anaplastic large 67 Hormone Refractory Prostate Cancer 67 recurrent metastatic ovarian cancer 66 Randomized Phase II 66 Adjuvant Treatment 66 Meets Primary Endpoint 66 Completes Patient Enrollment 65 Heterozygous Familial Hypercholesterolemia 65 Refractory Hodgkin Lymphoma 65 Prospective Randomized 65 Prednisone Against Refractory 65 Trial Evaluating 64 Relapsed Refractory 64 dependent kinase inhibitor 64 refractory cutaneous T 64 Diffuse Large B 64 metastatic malignant 64 Study Evaluating 64 Phase III Pivotal 64 Demonstrates Positive 64 ovarian esophageal 64 Glioblastoma Multiforme 64 Renal Cell Carcinoma 64 Improves Outcomes 64 Completes Enrollment 64 Pooled Analysis 63 Phase #b/#a clinical 63 CYT# potent vascular disrupting 63 pralatrexate injection folate analogue 63 R roscovitine CDK cyclin 63 Non Alcoholic Steatohepatitis 63 Metastatic Melanoma 63 evaluating picoplatin 63 Pivotal Phase 63 Patients Treated With 63 Initiate Phase III 63 Tyrosine Kinase Inhibitor 63 dasatinib Sprycel ® 63 Hsp# Inhibitor 63 Relapsed Multiple Myeloma 63 Cutaneous T 63 Antitumor Activity 63 Adjuvant Chemotherapy 63 PsA ulcerative colitis 63 II Clinical Trial 63 Oral Fingolimod 63 Phase 2a Clinical Trial 63 Phase 2b Study 63 Patient Enrollment 63 Teva Provides Update 63 Cardiac Resynchronization 63 Phase 2b Trial 63 Brentuximab Vedotin SGN 62 NASH Huntington 62 Malignant Glioma 62 advanced metastatic renal 62 Successfully Completes Phase 62 Glufosfamide 62 PROTECT AF 62 Phase IIb Clinical Trial 62 Philadelphia Chromosome Positive 62 Randomized Phase 62 Personalized Immunotherapy 62 Improves Survival 62 refractory chronic lymphocytic 62 VEGFR2 inhibitor 62 Granted Orphan Drug 62 Idiopathic Pulmonary Fibrosis 62 Tanespimycin 62 Initiates Phase II 62 Recurrent Glioblastoma 62 IL# PE#QQR 62 intravesical infusion therapy 62 Phase 2a Trial 62 Demonstrates Sustained 62 Advanced Melanoma 62 Therapy Improves 62 Pharmacokinetics PK 62 recurrent NSCLC 62 Randomized Double Blind 62 FOLOTYN ® 62 IgG1 monoclonal antibody 62 stage IIIb IV 62 Pemetrexed 62 hypertrichosis occurred 62 Epithelial Ovarian Cancer 62 Acute Exacerbations 62 Relapsing Multiple Sclerosis 62 INSPIRE Trial Phase III 62 Phase IIa Clinical Trial 62 oral dual endothelin 62 Achieves Primary Endpoint 62 monoclonal antibody IgG1 Mab 62 Clinical Trial Results 62 Kit CD# positive 62 Initiates Enrollment 62 Telik logo TELINTRA 62 Severe Sepsis 62 Long Term Efficacy 62 Efficacy Trial 62 Immunotherapeutic 62 novel VDA molecule 62 Drug Induced 62 Vidaza ® 62 Hodgkin lymphoma HL 62 Diabetic Macular Edema DME 62 R lenalidomide 61 PEGylated Fab fragment 61 Investigational Treatment 61 IN PATIENTS WITH 61 Treatment Naive Patients 61 ® lenalidomide 61 Appears Safe 61 Agonist MABA program 61 novel orally inhaled 61 Hormone Receptor Positive 61 essential thrombocythemia ET 61 Heart Failure Patients 61 Atypical Hemolytic Uremic Syndrome 61 Sipuleucel T 61 indolent follicular non 61 LHRH receptor positive 61 Hedgehog Pathway Inhibitor 61 Relapsing Remitting Multiple Sclerosis 61 Soft Tissue Sarcoma 61 Oncolytic Reovirus 61 MKC# MT 61 Bosutinib 61 Advanced Renal Cell 61 Phase IIb Trial 61 treatment naive genotype 61 3 registrational trial 61 Phase III Clinical Trial 61 Novel Oral 61 Therapeutic Efficacy 61 Randomised 61 Anthracycline 61 Degarelix 61 Chronic Lymphocytic Leukemia 61 See CLINICAL PHARMACOLOGY 61 Randomized Double blind 61 Myelofibrosis 61 Prostate AdenoCarcinoma Treatment 61 interferon beta 1a infertility 61 Myelodysplastic Syndrome MDS 61 CDK cyclin dependent 61 recurrent glioblastoma multiforme 61 interferon alpha IFN 61 Shows Promise Against 61 HDAC Inhibitor 61 ATRA IV 61 BR.# 61 J Am Acad 61 Humanized Anti 61 metastatic pancreatic 61 Adenoma 61 Unresectable 61 Effectively Treats 61 Decompensated Heart Failure 61 Begins Dosing 61 Oral Calcitonin 61 cisplatin gemcitabine 61 acute PAO 61 BRIM2 61 Initiates Clinical Trial 61 Controlled Trial 61 Previously Treated 61 Limb Ischemia 61 Presents Preclinical Data 61 Unstable Angina 61 Commences Phase 61 unique alkylating agent 61 Treatment Resistant 61 catheter occlusion 61 MAGE A3 ASCI 61 nilotinib Tasigna ® 61 Dose Escalation 61 CIMZIA TM certolizumab pegol 61 Prolongs Survival 61 Ovarian Cancers 61 Initiate Phase 61 Motexafin Gadolinium 61 Hypertensive Patients 61 non nucleoside inhibitor 61 Epratuzumab 61 AN# topical anti 61 Leukemias 61 Sapacitabine 61 Treatment Shows Promise 61 TNFerade TM 61 oral ridaforolimus 61 Microplasmin 61 Hepatocellular Carcinoma 61 Subgroup Analysis 61 metastatic colorectal 61 Slows Progression 61 Phase III multicenter 61 number NCT# ClinicalTrials.gov 61 First Patient Enrolled 61 Platinol ® 61 Paclitaxel Carboplatin 61 cell lymphoma CTCL 60 Patients Receiving 60 leukemia AML 60 Initiates Phase III 60 MEK Inhibitor 60 Anti Tumor 60 trial evaluating PRX# 60 evaluating satraplatin plus 60 Presents Positive 60 biliary tract cancer 60 Acute Myocardial Infarction 60 Pegloticase 60 Dementia Related Psychosis 60 Romidepsin 60 evaluating Actimmune 60 Vitrasert R 60 Single Dose 60 Files IND 60 Pulmonary Arterial Hypertension 60 FUSILEV enhances 60 Initiates Phase 2b 60 Demonstrates Efficacy 60 pan histone deacetylase 60 Preclinical Data 60 Myocardial Ischemia 60 Clinical Trial Evaluating 60 cell carcinoma RCC 60 Onyx Pharmaceuticals Announces 60 cutaneous T 60 Anti Tumor Activity 60 Embolization 60 Chronic Myeloid Leukemia 60 Slow Progression 60 Selective Internal 60 HCV SPRINT 60 Efficacy Results 60 Endologix Powerlink System 60 Drug Prevents 60 retinal vein occlusion induced 60 VICTOR E3 60 Deforolimus 60 Enlarged Prostate 60 influenza BCX# purine nucleoside 60 complement inhibitor eculizumab 60 sunitinib Sutent ® 60 FDA APPROVES 60 Aurora Kinase 60 selective modulator 60 Endovascular Valve Edge 60 Node Positive 60 virus HCV protease inhibitor 60 Abciximab 60 Combination Treatment 60 HER2 Positive Breast Cancer 60 Relapsed 60 Cerebril TM 60 PEGINTRON TM 60 Antigen Specific 60 Synta Announces 60 myelodysplastic myeloproliferative diseases 60 Desvenlafaxine Succinate 60 Xenografts 60 Confirmatory Phase 60 Non Alcoholic Fatty 60 + Perifosine Evaluation 60 Phase III Trial 60 Carcinoma 60 Pivotal Phase III 60 mGluR5 negative 60 relapsed refractory multiple myeloma 60 orally administered inhibitor 60 myocardial infarction ventricular fibrillation 60 Pivotal Clinical Trial 60 metastatic colorectal carcinoma 60 Tumor Response 60 keloid scarring 60 Squamous Cell Carcinoma 60 Occlusive Disease 60 PNP inhibitor 60 AVN# Phase 60 R Saizen R 60 evaluating intravenous picoplatin 60 5 fluorouracil leucovorin 60 ELADUR ™ 60 ISTODAX ® 60 sarcoma melanoma 60 Lymphocytic 60 Refractory Angina 60 ADVANCE ILLUMINATE 60 candidates Azedra TM 60 Tesetaxel 60 Resistant Hypertension 60 Novel Inhibitor 60 Cancer Incidence Mortality 60 Pralatrexate 60 familial amyloidotic polyneuropathy FAP 60 Hepatocellular 60 Chronic Heart Failure 59 metastatic GIST 59 ThermoDox R 59 Voreloxin 59 erlotinib Tarceva ® 59 Pivotal Study 59 Initiates Phase 59 Receives Orphan Drug Designation 59 Patients Undergoing 59 NICE Recommends 59 NS5B polymerase 59 Non Invasive Treatment 59 IMPACT DCM 59 cancer mCRC 59 ERBITUX cetuximab 59 Physician Insights 59 aneurysms AAA 59 SPRYCEL ® 59 ALN VSP Phase 59 Systemic Sclerosis 59 Randomized Study 59 JAK2 Inhibitor 59 Metastatic Colorectal Cancer 59 MEND CABG II 59 dasatinib Sprycel 59 Myelodysplastic Syndrome 59 Antitumor activity 59 TRANSDUR ® 59 Preclinical Study 59 Preclinical Models 59 GRNOPC1 contains 59 Cell Lymphoma 59 5 FU leucovorin 59 Drug Candidate 59 Alzheimer disease cognitive impairment 59 Aflibercept 59 carcinoma mCRC 59 CYP#A# isoenzyme 59 dose escalation clinical 59 minimally symptomatic 59 approved incretin mimetic 59 Controlled Study 59 Proc Am Soc 59 compound INCB# 59 Shows Efficacy 59 metastatic renal 59 Early Relapsing Multiple 59 alfa 2a 59 Factor Receptor 59 chronic myeloid 59 cyclophosphamide methotrexate 59 non splenectomized 59 Elderly Patients 59 RCW Breast Cancer 59 Azacitidine 59 modified glutathione analog 59 papillary renal cell carcinoma 59 Seliciclib CYC# 59 Neovascular Age Related Macular 59 Glatiramer Acetate 59 Licenses Novel 59 refractory NSCLC 59 FDA Accepts 59 investigational oral inhibitor 59 Dose Ranging Study 59 recurrent malignant glioma 59 CEL SCI Phase III 59 By JENNIFER LEARN 59 Epidermal Growth Factor Receptor 59 de novo kidney transplant 59 FOLFOX6 chemotherapy regimen 59 THAT ARE DIFFICULT TO 59 Shows Statistically Significant 59 Investigational Oral 59 See CONTRAINDICATIONS 59 ZACTIMA 59 oral nucleoside analogue 59 Subarachnoid Hemorrhage 59 LymphoStat B TM 59 Naive Patients 59 Placebo Controlled 59 Accelerated Partial Breast Irradiation 59 Frozen Shoulder syndrome Adhesive 59 Renal Impairment 59 including eniluracil ADH 59 See WARNINGS 59 Phase IIIb 59 Multiple Myeloma MM 59 demonstrated antitumor activity 59 Albuferon TM 59 Complicated Skin 59 HALTS 59 Pivotal Trial 59 dextromethorphan quinidine 59 ThermoDox ® clinical 59 Mg Usa 59 registrational Phase 59 Ridaforolimus 59 evaluating tivozanib 59 Dupuytren Disease 59 pulmonary alveolar 59 TNF Tumor Necrosis Factor 59 pediatric Crohn disease 59 fistulizing Crohn disease 59 myelofibrosis polycythemia vera 59 AAG geldanamycin analog 59 Abstract Accepted 59 unresectable Stage III 59 ZOLINZA 59 Placebo Controlled Trial 59 Enrolls First 59 Central Retinal Vein 59 Aggressive Reduction 59 KRN# 59 post herpetic neuralgia PHN 59 HER2 Positive 59 Previously Untreated 59 Patients Suffering 59 phase III isavuconazole 59 Drug Shows Promise 59 undergoing elective percutaneous 59 MKC# 59 Newly Diagnosed Multiple Myeloma 59 D aspartate NMDA receptor 59 novel emulsion formulation 59 Enzastaurin 59 candidate XP# 59 class anticancer quinolone 59 NDA Submission 59 CONQUER OB 59 prostate cancer HRPC 59 paclitaxel Taxol R 59 EOquin TM phase 59 Ribavirin causes 59 Primary Hypercholesterolemia 59 Bayer HealthCare Onyx Pharmaceuticals 59 phase IIb clinical 59 dual endothelin receptor antagonist 59 Diabetic Foot Ulcer 59 TM Everolimus Eluting 59 resistant hormone refractory 59 Multicenter Randomized Double 59 Bone Metastases 59 BCG refractory carcinoma 59 Therapy Reduces 59 Alimentary Tract 59 Phase 1b clinical trials 59 HRPC ovarian cancer 59 monoclonal antibody conjugated 58 oral Janus kinase 58 Endometrial Cancer 58 hyperplasia BPH 58 Metastatic Renal Cell Carcinoma 58 acute mania 58 Placebo controlled 58 Chronic Hepatitis C 58 Castration Resistant Prostate Cancer 58 Initiated Phase 58 Intravitreal 58 follicular Non Hodgkin 58 arsenic trioxide injection 58 CYP#A# substrate 58 Prognostic Significance 58 bone marrow reticulin deposition 58 Diabetic Neuropathy 58 evaluating Xcytrin 58 candidate CRLX# 58 hypoxia activated prodrug 58 relapsed Acute Myeloid 58 CML CP 58 Neuroendocrine Tumors 58 Intracranial Aneurysms 58 metastatic castration resistant 58 Initiate Clinical Trial 58 Cervical Dystonia 58 TNFerade ™ 58 Vicriviroc 58 GOUT 58 Peginterferon Alfa 2a 58 sapacitabine CYC# 58 EnteroMedics proprietary neuroblocking technology 58 osteolytic bone disease 58 BEYONCE AND 58 administering VIVITROL 58 Anti VEGF 58 acute myeloid 58 Perifosine KRX 58 evaluating pirfenidone 58 Successfully Treats 58 APPRAISE 58 Inhibits 58 ACTEMRA TM 58 phase IIb study 58 ongoing Phase 1b 58 Treatment Experienced 58 fosbretabulin 58 Treating Chronic 58 irinotecan doxorubicin oxaliplatin paclitaxel 58 fallopian tube cancers 58 NU# direct 58 occlusion PAO 58 Study Shows Promise 58 Lupus Nephritis 58 treat chronic sinusitis 58 intravitreal insert 58 Postmenopausal Women 58 VIVITROL ® 58 Coronary Artery Bypass Graft 58 AKT inhibitor 58 icatibant 58 Xcytrin R 58 Carotid Revascularization Endarterectomy vs. 58 Dose Ranging 58 opioid naive 58 R sorafenib tablets 58 Lenocta TM 58 TO AVOID PREGNANCY WHILE 58 Cannabinor 58 Shows Promising 58 Advaxis Phase 58 Plaque Psoriasis 58 FDA Okays 58 lintuzumab SGN 58 refractory systemic anaplastic 58 Submits NDA 58 Myelodysplastic Syndromes 58 oncolytic virus therapies 58 Adenocarcinoma 58 CAPACITY trials 58 Edge STudy 58 multicenter Phase II 58 TM pralatrexate injection 58 Irbesartan 58 Aliskiren 58 Chronic Sinusitis 58 Mouse Model 58 External Beam 58 rALLy clinical trial 58 metastatic ocular 58 Chronic Myelogenous Leukemia 58 Convection Enhanced Delivery 58 refractory metastatic 58 Fixed Dose 58 Vascular Disrupting Agent 58 oral prodrug 58 treatment naïve genotype 58 Tha Carter Tha Carter 58 Phase 1b Clinical Trial 58 Antiangiogenic 58 docetaxel cisplatin 58 gastrointestinal stromal tumor GIST 58 receptor tyrosine kinase inhibitor 58 Cloretazine ® 58 ADAGIO 58 previously untreated follicular 58 pharmacogenomic translational research 58 Disease Progression 58 Myocardial Infarction Study 58 Gene Mutation Linked 58 Frontman Discusses 58 Monotherapy 58 Peginterferon alfa 2b 58 CG# oncolytic virus 58 Daclizumab 58 treat benign prostatic 58 Carcinoid Syndrome 58 Matrix Phase 2b 58 investigational humanized monoclonal antibody 58 Peginterferon 58 Nesiritide 58 stage IIIB 58 non resectable metastatic 58 Mylan Receives Approval 58 Amgen Neulasta R 58 Cimzia TM 58 aflibercept VEGF Trap 58 moderate hepatic impairment 58 Dose Escalation Study 58 Teriflunomide 58 oropharyngeal candidiasis OPC 58 Stereotactic Body Radiation Therapy 58 accumulate preferentially 58 irinotecan cisplatin 58 REUNITE FOR 58 Begins Recording 58 PDX pralatrexate 58 Telaprevir VX 58 TMC# C# 58 mitoxantrone plus 58 OMP #R# 58 Neoadjuvant 58 Advanced Solid Tumors 58 Capsulitis 58 Diabetic Nephropathy 58 PROTEGE 58 renal failure interstitial lung 58 imetelstat GRN#L 58 Radioimmunotherapy 58 chronic thromboembolic pulmonary 58 hypereosinophilic syndrome 58 Eluting Stent 58 Plus Ribavirin 58 interferon gamma 1b 58 Refractory Peripheral T 58 huN# DM1 58 kidney urologic 58 Allogeneic 58 Motesanib 58 docetaxel Taxotere R 58 receiving chemoradiation therapy 58 Paraplatin ® 58 vinca alkaloid 58 Acute Decompensated Heart Failure 58 Uterine Fibroid Embolization 58 via intradermal injections 58 metastatic castrate resistant 58 Folfox 58 Liver Metastases 58 arthritis PsA 57 lead Aganocide compound 57 receiving INTRON 57 Hepatocellular Carcinoma HCC 57 orally inhaled migraine 57 Immunomodulatory 57 Hematology Molecular Pathology 57 Novel Mechanism 57 Increased Mortality 57 Metastatic Prostate Cancer 57 Bezielle 57 Anticancer Activity 57 acute peptic ulcer 57 NEXT ALBUM 57 Receives Approvable Letter 57 Ischemic 57 non resectable 57 Newly Diagnosed 57 randomized Phase IIb 57 inflammatory PDE 57 Diabetic Macular Edema 57 develop HBV reactivation 57 generation purine nucleoside 57 Recurrent Breast Cancer 57 PEGylated interferon beta 1a 57 GVAX ® 57 metastatic neuroendocrine tumors 57 randomized controlled multicenter 57 Venous Thromboembolism 57 subependymal giant cell 57 Carcinomas 57 Toxicities 57 plasma kallikrein inhibitor 57 gastrointestinal stromal tumors GIST 57 steroid refractory ulcerative 57 OAB overactive bladder 57 Metastases 57 Bronchiectasis 57 Orally Active 57 Solazed TM 57 Safinamide 57 Omacetaxine 57 relapsed MM 57 CYP#A# CYP#D# 57 thalidomide Thalomid 57 Well Tolerated 57 Rare Genetic 57 Namenda Memantine HCl 57 Acute myeloid leukemia 57 refractory acute myeloid 57 TNF Blockers 57 MVA MUC1 IL2 57 Seliciclib 57 severe oral mucositis 57 Vaccine Protects Against 57 MKC# MKC# PP 57 agonistic human 57 RCW breast cancer 57 Pivotal Phase II 57 6 sulfatase 57 dimebon latrepirdine 57 Thromboembolism 57 included exfoliative dermatitis 57 targeted radiotherapeutic 57 Bortezomib 57 LymphoStat B belimumab 57 advanced fludarabine refractory 57 Relapsed Refractory Multiple Myeloma 57 IND Filing 57 Double Blind Placebo 57 Zenvia ™ 57 serum phosphorous 57 5 Fluorouracil 57 Syncria R 57 Cardiotoxicity 57 PEGINTRON REBETOL combination 57 IMPDH inhibitor 57 Phase Ib Clinical Trial 57 FRONTMAN 57 Infected Patients 57 hypothyroidism hyperglycemia hypotension arrhythmihemorrhagic colitis development 57 Improved Survival 57 Syndax Pharmaceuticals Inc. 57 MEND CABG 57 Secondary Hyperparathyroidism 57 Dapagliflozin 57 PREVAIL 57 erythematosus 57 Epothilone D 57 signal detection CTSD 57 SUCCEED trial 57 Pafuramidine 57 injectable suspension GABITRIL 57 multi kinase inhibitor 57 TRANSDUR ™ 57 Predict Response 57 HGS ETR1 mapatumumab 57 unresectable locally advanced 57 Xeloda ® 57 Malignant Melanoma 57 induced macular edema 57 Progenitor Cells 57 Papillary 57 Elestrin ® 57 docetaxel Taxotere ® 57 First Patient Dosed 57 Stage IIB 57 Enzyme Replacement Therapy 57 TM Drug Eluting 57 TTF Therapy 57 rALLy 57 Romiplostim 57 non thiazolidinedione TZD 57 Intervention Effectiveness 57 antibody MAb 57 cladribine Cladribine Tablets 57 T Cell Lymphoma 57 Proves Effective 57 evaluating carfilzomib 57 Treatment Reduces 57 Commence Phase 57 Silodosin 57 Aneurysm Repair 57 known dihydropyrimidine dehydrogenase 57 IMPACT IMmunotherapy 57 relapsing remitting MS RRMS 57 trastuzumab Herceptin R 57 Newly Diagnosed Patients 57 recurrent metastatic 57 Clinical Efficacy 57 FROM PRISON 57 PREGNANT PROCHIEVE ® 57 Survival Benefit 57 diabetic peripheral neuropathic DPN 57 Decitabine 57 B Cell Malignancies 57 Ophena TM 57 YOUR LOCAL ANIMAL SHELTER 57 Genasense ® 57 Hematological Malignancies 57 Solzira ™ 57 RNAi Therapeutic 57 corticotropin injection 57 Adjunctive Therapy 57 Completes Patient Enrolment 57 class mGluR5 inhibitor 57 personalized cellular immunotherapy 57 comparing alemtuzumab 57 Randomized Controlled Trial 57 STRIDE PD 57 B Cell Lymphoma 57 Cancer Patients Treated 57 Drug Fails 57 NCCN Updates 57 Hematological Cancers 57 Hypertrophy 57 recurrent squamous cell carcinoma 57 Multicenter Randomized 57 biologic antibody 57 Acute Myelogenous Leukemia 57 asymptomatic metastatic 57 huC# DM4 57 Demonstrates Significant 57 unresectable stage 57 Launches Generic Version 57 Phase Ib IIa 57 Prospective Multicenter 57 Progressive Multifocal Leukoencephalopathy 57 Breast Cancer Recurrence 57 humanized therapeutic 57 Metabolic Efficiency 57 evaluating ASA# 57 Kinase Inhibitors 57 ALN HPN 57 data management Clintrial 57 lexidronam injection 57 Inc. Nasdaq OXGN 57 NicVAX TM 57 Pruvel TM 57 Annamycin 57 allosteric modulator NAM 57 Meta Analysis 57 Randomized Double Blind Placebo 57 Adenoviral 57 humanized interleukin 6 57 R tiagabine hydrochloride NUVIGIL 57 alvespimycin 57 multicenter randomized controlled 57 Tezampanel 57 cancer neuroendocrine tumor 57 Renal Cell Cancer 57 plus gemcitabine 57 ® chorionic gonadotropin 57 ST Segment Elevation 57 Known hypersensitivity 57 CCX# B 57 registrational trial 57 Aeolus Pharmaceuticals Announces 57 Crofelemer budesonide foam 57 metastatic androgen independent 57 squamous non 57 Renal Cancer 57 Spectrum Pharmaceuticals Announces 57 Cell Lung Cancer 56 GW# [003] 56 controlled multicenter Phase 56 imatinib Gleevec ® 56 phase IIIb 56 refractory AML 56 epithelial ovarian 56 FOLFOX6 56 Investigational Compound 56 COPEGUS R 56 Horizant ™ 56 ELACYT 56 relapsing multiple sclerosis 56 Advanced Colorectal Cancer 56 Pertuzumab 56 Hypoactive Sexual Desire Disorder 56 AVASTIN 56 Mycophenolate Mofetil 56 BRIM3 56 polycythemia vera PV 56 product platforms AZX# 56 evaluating satraplatin 56 Left Ventricular Dysfunction 56 resistant ovarian cancer 56 Drug Resistant 56 AA Amyloidosis 56 gemcitabine Gemzar 56 cromolyn sodium 56 acyclovir Lauriad R 56 autologous cellular immunotherapy 56 tumors GIST 56 NPC 1C 56 liposomal formulation 56 octreotide implant 56 Endothelial Cells 56 IND Application 56 Parathyroid Hormone 56 lymphoma CTCL 56 PROACT Phase 2 56 Unfractionated Heparin 56 relapsed leukemia 56 dose escalation phase 56 Overactive Bladder OAB 56 sorafenib tablets 56 Paroxysmal Atrial Fibrillation 56 Amrubicin 56 Ozarelix 56 Antihypertensive 56 Completes Dosing 56 Is Well Tolerated 56 albiglutide currently 56 Curaxin CBLC# 56 RISKS UNCERTAINTIES AND ASSUMPTIONS 56 taxane chemotherapy administered 56 Fluorouracil 56 Phase IIA 56 multicenter randomized placebo controlled 56 advanced hepatocellular carcinoma 56 PI3K/Akt pathway inhibitor 56 Cerebral Amyloid Angiopathy 56 Oral Formulation 56 Phase III ADT 56 Phase Ib clinical 56 castrate resistant prostate cancer 56 MELAS 56 refractory metastatic colorectal cancer 56 corticosteroid dexamethasone 56 Phase 2a clinical 56 irinotecan containing 56 novel tubulin binding 56 HCV NS5B polymerase 56 CLARITY study 56 Patients Treated 56 randomized controlled Phase 56 Sustained Efficacy 56 Raloxifene STAR 56 investigational monoclonal antibody 56 atypical Hemolytic Uremic Syndrome 56 Zarnestra 56 EDEMA4 56 amalgam fillings mercury vapor 56 phase IIb trial 56 gefitinib Iressa 56 PRN FDA Approves 56 Clot Busting 56 Gleevec resistant 56 stage IIIb 56 pseudobulbar affect PBA 56 non metastatic osteosarcoma 56 FEMALES SHOULD BE ADVISED 56 Gene Linked 56 IIa Clinical Trial 56 C1 INH deficiency 56 gastrointestinal stromal tumor 56 Dendritic Cells 56 Telik Announces 56 platinum refractory 56 IMiDs R 56 Ovitrelle R Serostim 56 Chemotherapeutic Agents 56 CARE HF 56 allosteric modulator PAM 56 blinded randomized placebo controlled 56 triggers apoptosis programmed 56 Kinase Inhibitor 56 Enrolling Patients 56 Alemtuzumab 56 PKC# 56 ENDEAVOR IV 56 LUX Lung 56 HER2 positive metastatic breast 56 XL# anticancer compounds 56 Localized Prostate Cancer 56 Radiofrequency Ablation 56 metastatic HRPC 56 Combination Clinical Trial 56 bladder ovarian 56 evaluating mipomersen 56 particularly SANCTURA XR 56 refractory multiple myeloma 56 landmark ATHENA 56 Second Pivotal Phase 56 multicenter prospective 56 Lung Cancer Patients 56 Submits Biologics License Application 56 ARRY # 56 Ovarian Cancer Patients 56 individualized cellular immunotherapy 56 damage cirrhosis liver 56 recombinant PSMA vaccine 56 Hypercholesterolemia 56 following fluoropyrimidine oxaliplatin 56 Knee Osteoarthritis 56 EQUIP OB 56 Nilotinib 56 Solid Tumors 56 Recurrent Chest Wall 56 Targeted Therapy 56 steroid refractory GvHD 56 oral ghrelin agonist 56 naïve HCV 56 evaluating T DM1 56 Finishes Recording 56 Empatic ™ 56 ® natalizumab 56 pancreatic colon 56 visceral metastases 56 Phase III Psoriasis 56 antibody MT# 56 Mantle Cell Lymphoma 56 Chronic lymphocytic leukemia 56 EMD # 56 Ocrelizumab 56 Breast Cancer Cells 56 visilizumab 56 albiglutide 56 RELOVAIR ™ 56 mapatumumab 56 #I TM# 56 HGS ETR2 56 myeloproliferative diseases 56 Elagolix 56 Taxane 56 Pegylated Liposomal Doxorubicin 56 Tumor Growth 56 CAPRIE 56 HCV Protease Inhibitor 56 PARGLUVA 56 Chronic Lymphocytic Leukemia CLL 56 evaluating Prochymal 56 forodesine purine nucleoside phosphorylase 56 Carotid Stenting 56 Squamous 56 paclitaxel cisplatin 56 Lung Cancers 56 EDEMA3 56 elderly myelodysplastic syndromes